Clinical Trials Logo

Urothelial Carcinoma Recurrent clinical trials

View clinical trials related to Urothelial Carcinoma Recurrent.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05037279 Not yet recruiting - Bladder Cancer Clinical Trials

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

EVER
Start date: January 1, 2023
Phase: Phase 3
Study type: Interventional

The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.

NCT ID: NCT04064190 Not yet recruiting - Clinical trials for Advanced Urothelial Carcinoma

Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Start date: October 15, 2021
Phase: Phase 2
Study type: Interventional

This is Phase 2, open label, non randomized single arm study to determine whether the administration of vactosertib with durvalumab will provide meaningful increases in the Overall Response Rate (ORR) in patients with urothelial cancers that fail to achieve a response with anti-PD-1/PD-L1 based regimens